173 results about "Treatment dose" patented technology

Described herein are methods and apparatuses for reducing or eliminating skin glands (e.g., sebaceous, eccrine and apocrine) with an electric treatment. These apparatuses and methods may produce electroporation of cells by applying treatment dose having an energy density sufficient to eliminate or reduce the size of a target gland. Also described herein are methods for treating and / or preventing a disorder of a skin gland. For example, described herein are methods of treating sebaceous hyperplasia.

The invention discloses an image segmentation method for evaluating a hepatocellular carcinoma neutron therapy dose, and relates to the technical field of neutron therapy. A 3D U-Net GAN network model is trained through a medical image data set; a generator model and a discriminator model in a 3D U-Net GAN network model are alternately trained by using a real image and a false image randomly generated by the generator model, so that the trained generator model can generate a segmentation result which is more accurate and rich in details for a medical image; the trained discriminator model can more accurately evaluate the authenticity of the output of the generator model, and the trained network can accurately reflect the anatomical structure of the patient, the distribution condition of 10B in the body and the radionuclide dynamics condition when segmenting the medical image, so that the information in the medical image can be accurately and fully displayed, and the medical image segmentation efficiency can be improved. The application is convenient.

The invention relates to the technical field of medical drug dose analysis, in particular to a deep learning-based advanced nasopharyngeal carcinoma multi-target dose prediction system, which comprises a data acquisition module, an automatic sketching module, a dose prediction model construction module, a diversified dose generation module, a model training and optimization module, a result output and visualization module and the like. The automatic sketching module is used for realizing accurate and automatic sketching by using a multi-modal fusion and knowledge distillation framework; the dose prediction module accurately extracts features based on a UNetr network model and generates a multi-channel dose prediction result; the diversified dose generation module generates diversified complementary dose distribution through a specific method and a constraint mechanism; the model training and optimizing module effectively improves the model performance; the result output and visualization module presents results in various visual modes for doctors to make decisions; the nasopharynx cancer treatment dose prediction accuracy and individuation degree can be improved, the automatic sketching precision and efficiency can be improved, the clinical decision process can be optimized, and development of related technologies can be promoted.

The invention discloses a self-adaptive aid decision-making method, system and device for patient radiotherapy, and a medium, and relates to the field of smart medical treatment. The method comprises the following steps: standardizing and preprocessing multi-source original data; performing automatic segmentation and change detection on tumor and normal tissues based on the processed data; delineating a tumor target region and a normal tissue in radiotherapy in a detection result; generating radiation therapy dose distribution according to the sketching result; evaluating the radiation treatment dose distribution by adopting an optimization evaluation method to generate a plurality of alternative treatment schemes; determining an optimal treatment regimen based on the plurality of alternative treatment regimens; and performing radiotherapy based on the optimal treatment scheme, monitoring anatomical changes of the patient in real time in the radiotherapy process, and dynamically adjusting the optimal treatment scheme. According to the invention, a plurality of operations of patient radiotherapy can be effectively integrated, and precision and individuation of patient radiotherapy can be realized, so that complex changes in the treatment process can be better coped with, and the overall treatment effect can be improved.

The invention relates to the technical field of nasopharyngeal carcinoma radiotherapy, in particular to a nasopharyngeal carcinoma radiotherapy dose automatic prediction method based on deep learning, and the method comprises the following steps: S1, analyzing obtained original data; s2, writing a program to pre-process all the original data in batches; s3, calculating a corresponding dose volume histogram according to the anatomical contour and the patient dose distribution; and S4, inputting the preprocessed data into a designed deep learning model for dose distribution training and prediction, and comparing with an existing dose prediction method to verify the innovativeness and feasibility of the scheme. Dose prediction is automatically carried out through the deep learning model, manual rule design is not needed, high-quality dose distribution can be rapidly generated, batch preprocessing is carried out on all original data, dose distribution training and prediction are carried out by inputting the data into the designed deep learning model, the calculation performance is improved, and the method is suitable for large-scale popularization and application. And the training and reasoning efficiency is improved.

The invention discloses an infusion detection and control device for counting the infusion amount, and particularly relates to the technical field of infusion control, the infusion detection and control device comprises two drip chamber covers covering the top end of a drip chamber, a clamping stop assembly used for blocking liquid medicine from dripping is arranged on the upper portion in each drip chamber cover, and photoelectric sensors are installed on the lower portions in the two drip chamber covers; each photoelectric sensor comprises an emitter and a receiver, and liquid drops in the drip chamber are detected by the receiver when penetrating through the space between the two photoelectric sensors; the infusion apparatus further comprises a drip chamber rotating assembly covering the outer end of the infusion tube, a microcontroller used for receiving information sent by the photoelectric sensor to conduct medicine drop statistics is installed on the drip chamber rotating assembly, and the microcontroller controls the clamping and stopping assembly to stop continuous dripping of medicine liquid according to statistical data. The number of liquid drops in the drip chamber is directly counted through the photoelectric sensor, continuous conveying of liquid medicine is stopped in time through the drip chamber rotating assembly and the clamping and stopping assembly, and the treatment dosage of the liquid medicine conveyed into the body of a patient is accurately controlled.

This application relates the use of a combination of a membrane-associated tyrosine and threonine- specific CDC2-inhibitory kinase (Myt1) inhibitor with a Weel inhibitors in treating cancer or inducing cell death. The synergistic effect of the combination results in a subtherapeutic dose or a reduced dosing schedule of the Myt1 inhibitor, the Wee1 inhibitor, or both relative to a monotherapy of either the Myt1 inhibitor or the Wee1 inhibitor in isolation.

The invention belongs to the technical field of exosome modification, and particularly relates to an exosome modification method for connecting a target protein to the surface of an exosome by utilizing NHS-PEG-NHS to achieve a targeting or treatment effect, and application of the exosome modification method in targeted central nervous system demyelination disease treatment. In particular to a technology for modifying an exosome to enable the exosome to have targeting property and a preparation method of the exosome. NHS-PEG-NHS is used as a connecting substance, and protein, polypeptide and substances with primary amine groups on the surface can be connected to the surface of an exosome membrane. The modified exosome can load drugs and can be accurately delivered to tissues expressing specific proteins or polypeptides through oral administration, so that the bioavailability and the treatment effect of the drugs are remarkably improved. Taking the NG2 antibody modified cow milk exosome as an example, the NG2 antibody is connected to the surface of the cow milk exosome to target the central demyelination focus area, so that the effective therapeutic dose of the drug in the central focus area is achieved through oral delivery.

The invention discloses a close-range radiotherapy plan optimization method and device based on a cumulative dose target. The method comprises the following steps: S1, importing current treatment data; s2, leading in a preorder treatment image and performing deformation registration to the current image; s3, mapping the preorder treatment dose to the current treatment image to serve as the background dose of the current treatment; s4, converting the dose data mapped to the current treatment image by the preorder treatment into a bioequivalent dose; s5, on the basis of the sketching data of the current treatment image and with reference to the clinical endangered organ dose limit value requirement, key area generation is carried out on each endangered organ; s6, based on the preorder treatment dosage, generating a corresponding organ-endangered high-risk dosage area and a target area insufficient area according to each organ-endangered dosage limit value and the target area prescription dosage; and S7, optimizing the treatment plan, and optimizing the treatment plan by taking the preorder treated dose and the sum of the planned dose to be optimized at the time to meet the clinical requirement as a target.

The invention discloses a mouse model for treating in-situ pulmonary nodules by using bacterial lysates as well as a construction method and application of the mouse model. The method comprises the following steps: constructing an in-situ pulmonary nodule KT mouse model, instilling adenovirus, randomly dividing the model into an in-situ pulmonary nodule control group and a treatment group, performing bacterial lysate administration on mice in the treatment group at the maximum treatment dosage of 35mg / kg / d, and administering the same dosage of PBS solution to the control group. According to the invention, the possibility of killing cancer cells and preventing precancerous lesion progression by promoting autoimmunity of mice through oral immunostimulation drugs is provided for the first time, namely, the curative effect and mechanism of new drugs are researched through a mouse model, so that the clinical indications of the drugs are widened, and the blank field of clinical pulmonary nodule drug treatment is supplemented.

The invention relates to a self-adaptive radiotherapy dose optimization method and device and a storage medium, which are used for optimizing dose distribution in radiotherapy. Through combination of deep reinforcement learning (DRL) and a heuristic algorithm (a particle swarm optimization algorithm), the method maximizes the dose of a tumor area, and protects surrounding normal tissues at the same time. Firstly, an anatomical structure and a tumor area of a patient are extracted through medical image data, and initial dose distribution is generated; then, the deep reinforcement learning agent adjusts dose distribution according to the dynamic anatomical change of the patient, a heuristic algorithm is further optimized, and a local optimal solution is avoided; real-time feedback in the treatment process is used for adjusting dose distribution, and accuracy and timeliness of a treatment scheme are ensured. Finally, the generated optimal dose distribution scheme is provided for a clinician to refer, dose maximization of the tumor area is ensured, and normal tissue is protected. According to the method, the precision and effect of radiotherapy are improved, and a personalized treatment scheme is provided.

Methods, devices, and systems for treating a region of interest (ROI) of skin of a subject or patient in need thereof are disclosed. Such a method of treating a ROI, in some embodiments, comprises irradiating a test region (TR) of the skin with a sub-therapeutic dose of electromagnetic radiation or with a series of sub -therapeutic doses, determining a tissue response of the TR, and generating one or more therapeutic dose parameters based at least in part on the tissue response of the TR. In some embodiments, the method further comprises irradiating the ROI with one or more therapeutic doses of electromagnetic radiation in accordance with the one or more therapeutic dose parameters.

A neural network is trained using a training corpus having a plurality of information features, each of the information features including both a reference radiation treatment dose and at least one corresponding post-treatment patient datum. By one approach, the at least one corresponding post-treatment patient datum comprises patient imagery such as, but not limited to, one or more computed tomography images. That trained neural network facilitates radiation treatment planning by generating resultant treatment efficacy probability information and resultant treatment complications probability information.

Electrically neutral complex compounds of formula I including any stereoisomer or E / Z isomer thereof wherein: M is Fe < 2 + >, Ru < 2 + >, Os < 2 + >, Co < 3 + >, Rh < 2 + >, Rh < 3 + >, Ir < 3 + >, Ni < 2 + >, Pd < 2 + >, Pt < 2 + > or Pt < 4 + >, in particular Ru < 2 + >; t and T'are H or (C1-C3)-alkyl; lig is a bidentate ligand, in particular 2, 2 '-dipyridyl (bpy) or 4, 7-diphenyl-1, 10-phenanthroline (BPhen); and A is an anion from a pharmaceutically acceptable acid, the electrically neutral complex compounds of formula I are useful in human therapy, in particular as photosensitizers (PS) in photodynamic therapy (PDT) of cancer, skin diseases, fungal infections or microbial infections. They are almost non-toxic under dark conditions at therapeutic doses and exhibit good to excellent photoactivity under hypoxic conditions. They can be used for PDT treatment of deep hypoxia tumors by using light within a far-infrared to near-infrared light treatment window.

The inhalation suspension preparation containing the SGC receptor stimulant comprises the SGC receptor stimulant with an effective therapeutic dose or pharmaceutically acceptable salt of the SGC receptor stimulant, and pharmaceutically acceptable auxiliary materials of the suspension preparation, the pharmaceutically acceptable auxiliary materials of the suspension preparation comprise at least one of a surfactant, a pH regulator, an osmotic pressure regulator and a metal complexing agent; the inhalation suspension preparation containing the riociguat shows good lung absorption efficiency, is beneficial to reaching the same or better treatment level by reducing the administration dosage, can directly act on a diseased region through an administration route, takes effect more quickly compared with oral administration of the riociguat, and has a good application prospect. Gastrointestinal discomfort and systemic hypotension side effects caused by gastrointestinal tract contact and absorption entering a circulatory system can be avoided, the treatment cycle of an oral dosage form dosage titration administration scheme is shortened, and a better treatment scheme is provided for relieving dyspnea and syncope symptoms of pulmonary hypertension patients treated at home.

Techniques for adjusting radiotherapy treatment for a patient in real-time are provided. The techniques include obtaining a training patient anatomy at a first time within a training radiotherapy treatment fraction after a training radiotherapy treatment dose has been delivered by a radiotherapy device; computing a deviation between the training patient anatomy at the first time and reference training patient anatomy during the training radiotherapy treatment fraction, wherein the reference training patient anatomy indicates a prescribed training dose parameter to be delivered within the training radiotherapy treatment fraction; applying the computed deviation to a machine learning model to estimate one or more intra-fraction radiotherapy treatment parameters of a function that provides a radiotherapy device parameter adjustment based on the one or more intra-fraction radiotherapy treatment parameters; and training the machine learning model to establish a relationship between the computed deviation and the one or more intra-fraction radiotherapy treatment parameters.

The present invention relates to a light therapy apparatus, system, and method to deliver light to a body organ, e.g., to directly contact the skin such as a scalp, via one or more light guides in therapeutic dosages from one or more light sources operating in a variety of wavelengths. One or more illumination assemblies may be fixedly coupled to two or more panel assemblies operably coupled to a substructure. The panel assemblies may be acted upon by one or more actuators to move the panel assemblies resulting in conformal contact with the body organ from a first position to a second position. The actuator may comprise a cable coupled to a motor, the cable operably coupled to each panel assembly, so that upon activation of the motor, the panel assemblies each move inwardly in an independent direction with respect to each other to conform to the body organ.

Methods and apparatuses for setting a therapeutic dose of a neuromodulator implanted into a patient. The therapeutic dose typically includes a therapeutic dose duration including a ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage. The methods and apparatuses may use a testing ramp to identify a peak modulation voltage that is patient-specific and provides a maximized therapeutic effect while remaining comfortably tolerable by the patient during the application of energy by the neuromodulator.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The present application relates to the field of intelligent medical treatment, in particular to a tumor treatment dosing regimen Pareto optimization method based on forward-backward stochastic differential equation. The present application unifies the terminal tumor load, dosing cost and treatment risk into the same stochastic control framework, can establish the Pareto optimality condition corresponding to the nonlinear model, and further converts into the implementable closed-loop state feedback control law in the LQ case. Through the combination with the numerical example and the Pareto frontier analysis, an implementable, interpretable and scalable technical path is provided for the multi-objective individualized treatment regimen design, which can solve the problem that the existing technology is difficult to uniformly process the terminal therapeutic effect, dosing consumption and cumulative risk, and difficult to obtain the implementable closed-loop feedback strategy under the forward-backward stochastic control framework.

To provide a method of treating a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including hematologic malignancies that are refractive to chemotherapeutic and / or hypomethylating agents.SOLUTION: The present invention provides a method of treating a chemo-refractory hematologic malignancy in a patient, wherein the method comprises administering to the patient a treatment dosage of a CD123×CD3 bispecific molecule, the dosage being effective to stimulate the killing of cells of the hematologic malignancy in the patient, thereby treating the malignancy.SELECTED DRAWING: None

The invention provides a BNCT treatment dose accelerated calculation method, a terminal and a treatment planning system. The method comprises the steps of equally dividing each voxel block into a first voxel block and a second voxel block based on a three-dimensional coordinate of each voxel block in a voxel model; alternately iteratively executing the parallel computing process of the first voxel block and the parallel computing process of the second voxel block on the basis of a pre-constructed computing dependency relationship, and obtaining the neutron ejection flow and the neutron flux of each voxel block until an iteration stop condition is met; wherein the dependency calculation relation includes that parallel calculation of the first voxel block depends on neutron outgoing flow of the second voxel block, and parallel calculation of the second voxel block depends on neutron outgoing flow of the first voxel block; and calculating the BNCT therapeutic dose based on the neutron flux of each voxel block. According to the method, on the premise of strictly guaranteeing the calculation precision, a large-scale parallel calculation task set can be formed, the iteration convergence period and the overall calculation time consumption are reduced to the maximum extent, and the requirement for clinically and rapidly calculating the BNCT treatment dose is met.

The present invention concerns dosimetry-related uses and methods that rely on a metastable technetium-99 (99mTc) radionuclide-comprising (dosimetric) radioimmunoconjugate (RIC) to evaluate or establish therapeutic doses of yttrium-90 (90Y) radionuclide-comprising (therapeutic) radioimmunoconjugates, both RICs targeting the same molecular target. More specifically, radioimmunoconjugates that comprise a CD66-binding component are used. Another aspect of the invention relates to Single Time Point dosimetry procedures replacing the need for traditionally used Multiple Time Point dosimetry procedures for yttrium-90 (90Y) radionuclide-comprising radioimmunoconjugates.

The endovenous treatment assembly comprises a wire element (1) for delivering treatment doses, such as for example an optical fiber, which is flexible and capable of being inserted, over part of its length, longitudinally into a vein (V), and a positioning and guiding part (2A), which is integral with the wire element (1) for delivering treatment doses so as to allow manipulation of the wire element (1) for delivering treatment doses by means of this part (2A), the wire element (1) for delivering treatment doses being able to slide in the direction of its length relative to said part (2A);the part (2A) comprises first means for guiding in translation a first portion (110a) of the wire element (1) for delivering treatment doses in the direction of its length and first mechanical assembly means (202, 203) allowing its removable mounting relative to a drive system (4), such that said first portion (110a) of the wire element (1) for delivering treatment doses can be positioned and guided by means of this part (2A) relative to the drive means of the drive system (4) for driving the wire element (1) for delivering treatment doses in the direction of its length at least in a first direction (R).;

The present invention provides a device, system, and method of using the same that can safely and effectively transmit therapeutic or germicidal ultraviolet (UV) radiation, such as UVC radiation or UVA radiation. [Solution] The treatment device comprises a base component and a head component. The head component has a distal portion and a proximal portion. The distal portion of the head component is configured to contact the target eyelid, and the proximal portion is configured to be attached to the base component. The distal portion of the head component is configured to transmit a therapeutic dose of energy from a plurality of energy sources, including an ultraviolet C (UVC) radiation source, an infrared (IR) radiation source, and an ultrasonic source. The plurality of energy sources are configured to transmit a therapeutic dose of energy to the target eyelid at a predetermined output when the distal portion of the head component contacts the eyelid.

Hydration of a larynx and / or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and / or NaCl) can achieve prophylactic and / or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and / or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 μm to approximately 15 μm or from approximately 15 μm to approximately 500 μm. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.

The invention belongs to the technical field of biological medicine, and particularly relates to application of coniferyl aldehyde in preparation of anti-cancer drugs. The invention discloses application of coniferyl aldehyde in preparation of anti-cancer drugs, coniferyl aldehyde can significantly inhibit invasion and migration ability of hepatocellular carcinoma cells, cancer cells cannot break through primary parts through key links such as interference of movement and adhesion of the cancer cells and degradation of extracellular matrixes, invasion of tumors to surrounding tissues is reduced, and the anti-cancer effect is improved. The occurrence rate of remote metastasis is reduced, the non-metastasis lifetime of the patient is prolonged, and more treatment time and survival opportunities are won for the patient; a large number of cell experiments and animal experiments prove that the medicine has no obvious liver and kidney toxicity under the treatment dosage, the tolerance of a patient to treatment is improved, the smooth proceeding of the treatment process is guaranteed, and the living quality of the patient is effectively improved.

The invention discloses an image segmentation method for evaluating a non-small cell lung cancer neutron treatment dose, and relates to the technical field of neutron therapy, and the method comprises the steps: carrying out the training of a 3D U-Net network model through a medical image data set, updating the network parameters and hyper-parameters in the 3D U-Net network model, so as to obtain a trained 3DU-Net network model, and carrying out the evaluation of the neutron treatment dose of the non-small cell lung cancer. In the aspect of processing three-dimensional volume data in an image, information of a space direction can be better reserved, segmentation of a three-dimensional structure can be more accurately carried out, and the segmentation form can accurately reflect an anatomical structure of a patient, a distribution condition of 10B in a body and a radionuclide dynamics condition. Therefore, the information in the medical image can be accurately and fully displayed, and application is facilitated.

The invention belongs to the technical field of biological medicine, and particularly relates to a heparin small molecule antagonist-quaternary ammonium salt macrocyclic compound and a preparation method thereof. The quaternary ammonium salt macrocyclic compound disclosed by the invention comprises three piperazine functionalized quaternary ammonium salt macrorings and four methylated quaternary ammonium salt macrorings; the quaternary ammonium salt macrocyclic compound can be used for preparing a heparin small molecule antagonist. The compound shows excellent antagonism efficiency on ungraded heparin and low-molecular-weight heparin, and shows a wide therapeutic dose window; and the antagonism efficiency and dosage window of the protamine are superior to those of clinically used protamine. Besides, in-vivo and in-vitro safety evaluation proves that the quaternary ammonium salt macrocycle has good biocompatibility, and shows clinical transformation potential as a protamine substitute as a small molecule antagonist.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.